Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CCNO divergent transcript (CCNO-DT) is a long non-coding RNA (lncRNA) gene, not a classical therapeutic target such as a receptor, enzyme, transporter, or transcription factor. There is no evidence suggesting it directly encodes a protein or possesses classical druggability features. It is annotated at the CCNO locus. Divergent transcripts are commonly transcribed from promoters in the direction opposite to the coding gene, typically lacking protein-coding potential but sometimes involved in transcriptional regulation. Such ncRNAs can influence gene expression, chromatin architecture, or transcriptional directionality, though specific functional data for CCNO-DT are lacking. There is currently no evidence that CCNO-DT encodes a protein, directly acts as a disease gene, or is used as a therapeutic target. CCNO-DT should not be confused with CCNO (Cyclin O), which encodes a protein involved in cell cycle regulation. It is a divergent transcript defined by its genomic location relative to the CCNO gene, with no established drug interactions, mechanism of action, or established role in disease. If more specific or tissue/disease-related information becomes available regarding CCNO-DT, those details would refine this profile; currently, it is best classified as a long non-coding RNA with unclear biological and therapeutic significance.
Not applicable; no reported mechanism as a drug target
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CCNO divergent transcript (CCNO-DT).